- Home
- TNGX vs SNN Comparison
TNGX vs SNN Comparison
Compare TNGX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | SNN |
|---|---|---|
| Founded | 2014 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 13.9B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | TNGX | SNN |
|---|---|---|
| Price | $8.84 | $32.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | $12.50 | ★ $32.83 |
| AVG Volume (30 Days) | ★ 2.5M | 568.5K |
| Earning Date | 11-04-2025 | 02-24-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | N/A | ★ 0.56 |
| Revenue | $66,501,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $52.80 | $7.71 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | ★ N/A | $28.42 |
| Revenue Growth | ★ 53.29 | 5.35 |
| 52 Week Low | $1.03 | $23.69 |
| 52 Week High | $11.20 | $38.79 |
Technical Indicators
Market Signals| Indicator | TNGX | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 47.04 |
| Support Level | $8.45 | $32.66 |
| Resistance Level | $9.00 | $33.25 |
| Average True Range (ATR) | 0.52 | 0.35 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 30.62 | 68.91 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.